Scientists at King’s College London have identified a promising new strategy for fighting Alzheimer’s disease that could address several of the condition’s damaging effects at the same time. Their research suggests that an experimental drug originally developed for spinal cord injuries may help repair damaged DNA, reduce inflammation, and target biological changes associated with the disease.
The drug, known as KCL-286, produced encouraging results in a mouse model of Alzheimer’s disease. Unlike treatments that focus primarily on the buildup of toxic proteins in the brain, this approach targets additional processes that can begin long before the disease reaches its advanced stages.
One particularly promising advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials as part of its earlier development. This could significantly shorten the path toward further clinical testing, although its effectiveness against Alzheimer’s in humans has not yet been established.
“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,” commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London.
The drug is a small molecule that can be taken by mouth, making it potentially more convenient to administer than treatments that require injections or infusions.
Why Alzheimer’s Disease Is So Difficult to Treat
Alzheimer’s disease involves a complicated series of changes in the brain, making it particularly challenging to develop effective treatments. Two of its best-known features are the abnormal accumulation of proteins called amyloid-beta and tau.
Amyloid-beta can collect into sticky deposits between nerve cells, while abnormal tau proteins can form tangles inside them. These changes interfere with normal brain function and are associated with the progressive loss of neurons, the specialized cells responsible for transmitting information throughout the brain.
Much of the effort to develop Alzheimer’s treatments has focused on these two proteins. Although medications that remove amyloid-beta have demonstrated modest but measurable clinical benefits, they do not fully address the many biological processes involved in the disease.
Researchers are increasingly investigating other changes that may contribute to Alzheimer’s, including damage to DNA and inflammation in the brain. Both can appear early in the disease process, making them potentially valuable targets for treatments designed to slow its progression.
In the new study, KCL-286 helped repair breaks in DNA and reduce inflammation in mice with Alzheimer’s-like disease. These findings suggest that targeting several harmful processes simultaneously could offer a broader approach than focusing on amyloid-beta or tau alone.
“Our findings demonstrate that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer’s disease progression. This highlights its potential as a disease-modifying therapy rather than simply addressing symptoms,” said Dr. Maria Goncalves, who project-managed the drug development.
How Vitamin A Pathways Could Help Fight Alzheimer’s
The drug works by activating a particular protein involved in the retinoic acid pathway, a biological system associated with how the body processes and uses vitamin A.
Vitamin A is best known for supporting healthy vision, but it also plays important roles in cellular development, gene regulation, and nervous system function. Retinoic acid, a substance derived from vitamin A, helps control the activity of genes involved in several essential biological processes.
Earlier research found that disruptions in this pathway were associated with the formation of amyloid-beta deposits in the brains of rats. These deposits resemble a major pathological feature of Alzheimer’s disease, suggesting that the pathway may be relevant to the condition.
KCL-286 activates a specific protein within this system, offering researchers a way to influence biological processes connected to brain health and cellular repair.
The drug had already demonstrated an ability to promote the repair of DNA double-strand breaks in earlier research involving neuropathic pain, a type of pain caused by damage or dysfunction in the nervous system.
That discovery led scientists to investigate whether the same mechanism might also help address DNA damage associated with Alzheimer’s disease.
Repairing a Dangerous Type of DNA Damage
DNA contains the genetic instructions that cells need to function properly. Although cells have natural systems for repairing damaged DNA, some forms of damage are particularly serious.
One example is a DNA double-strand break, which occurs when both strands of the DNA molecule are severed. These breaks can disrupt normal cellular activity and threaten cell survival if they are not properly repaired.
“DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges. We found that KCL-286 promotes repair of these breaks, allowing us to target a key feature of Alzheimer’s disease,” said Professor Corcoran.
The researchers had another reason to suspect that KCL-286 might be useful against Alzheimer’s. Previous work by the same team at King’s College London identified molecular pathways shared by acute spinal cord injury and Alzheimer’s disease.
Because the two conditions involve some overlapping biological mechanisms, the scientists believed that a drug developed to address nervous system damage after spinal cord injury might also improve certain Alzheimer’s-related changes in neurons.
Their new findings support that possibility, showing that KCL-286 can influence several cellular pathways involved in the disease.
A Promising New Direction for Alzheimer’s Treatment
The results highlight a potentially important shift in Alzheimer’s research. Rather than concentrating on one hallmark of the disease, scientists are exploring treatments that address several interconnected causes of brain damage.
KCL-286 is particularly interesting because it targets DNA damage and inflammation, two processes that can emerge early in Alzheimer’s progression. Its previous human safety testing also provides a potential advantage over entirely new drug candidates that have not yet entered clinical development.
However, the Alzheimer’s findings remain preclinical. Additional studies and human clinical trials will be necessary to determine whether the drug can safely slow disease progression or improve outcomes in patients.
Natasha Hill, one of the first authors on the paper, said: “To develop an effective treatment for Alzheimer’s disease, we need to tackle multiple aspects of the disease. KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.”
